Frontiers in medicine · 2025
The relationship between the intraocular position of dexamethasone intravitreal implant and post-injection intraocular pressure elevation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Dingxi, Chen Yue, Fu Xiaonan, Zhao Yongxia, Ji Lili, Qiu Yuanyuan, Li Sheng
Аннотация
OBJECTIVE: To investigate the relationship between the implantation position of dexamethasone intravitreal implant (DEX-I) and post-injection intraocular pressure (IOP) elevation.
METHODS: This retrospective study included 324 patients (332 eyes) who received at least one DEX-I injection between June 2020 and June 2024, with a follow-up period of at least 3 months. Patient demographics, diagnoses, and DEX-I implantation positions were recorded. The correlation between implantation position and post-injection IOP elevation was analyzed. IOP elevation was defined as an IOP greater than 25 mmHg and/or an increase of 10 mmHg from baseline. DEX-I implantation positions were defined as follows: P1: implant located in the vitreous near the ciliary body, anterior to the ora serrata (with or without ciliary body contact); P2: implant located in the vitreous from the ora serrata to the pre-equatorial region; P3: implant located in the post-equatorial vitreous. The equator was defined by the vortex veins.
RESULTS: During the follow-up period, 68 eyes (20.48%) experienced IOP elevation. Compared to P2 and P3, the P1 implantation position was significantly associated with a higher incidence of IOP elevation (p < 0.001) and was positively correlated with early IOP elevation (within 15 days post-injection) (r = 0.761; p < 0.001).
CONCLUSION: The P1 implantation is positively correlated with IOP elevation, particularly with early IOP elevation.
METHODS: This retrospective study included 324 patients (332 eyes) who received at least one DEX-I injection between June 2020 and June 2024, with a follow-up period of at least 3 months. Patient demographics, diagnoses, and DEX-I implantation positions were recorded. The correlation between implantation position and post-injection IOP elevation was analyzed. IOP elevation was defined as an IOP greater than 25 mmHg and/or an increase of 10 mmHg from baseline. DEX-I implantation positions were defined as follows: P1: implant located in the vitreous near the ciliary body, anterior to the ora serrata (with or without ciliary body contact); P2: implant located in the vitreous from the ora serrata to the pre-equatorial region; P3: implant located in the post-equatorial vitreous. The equator was defined by the vortex veins.
RESULTS: During the follow-up period, 68 eyes (20.48%) experienced IOP elevation. Compared to P2 and P3, the P1 implantation position was significantly associated with a higher incidence of IOP elevation (p < 0.001) and was positively correlated with early IOP elevation (within 15 days post-injection) (r = 0.761; p < 0.001).
CONCLUSION: The P1 implantation is positively correlated with IOP elevation, particularly with early IOP elevation.